Zobrazeno 1 - 10
of 253
pro vyhledávání: '"Xue Ning Yang"'
Autor:
Song Dong, PhD, Bingfa Yan, PhD, Si-Yang Liu, PhD, Xuan Gao, PhD, Hui-Zhao Hong, MD, Hong-Ji Li, MD, Wei Gao, PhD, Hong-Hong Yan, PhD, Si-Yang Maggie Liu, PhD, Hai-Yan Tu, PhD, Yi Pan, PhD, Qing Zhou, PhD, Xue-Ning Yang, PhD, Xue-Feng Xia, PhD, Xin Yi, PhD, Wen-Zhao Zhong, PhD, Yi-Long Wu, MD, Jia-Tao Zhang, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 6, Iss 1, Pp 100758- (2025)
Introduction: EGFR tyrosine kinase inhibitor (TKI) is the standard adjuvant treatment for patients with stages IB to IIIA EGFR-mutated NSCLC. Nevertheless, adapting this approach to include a molecular residual disease (MRD)-guided de-escalation stra
Externí odkaz:
https://doaj.org/article/53643bd155c048d5bc49ea739a649af6
Autor:
Yang-Si Li, Wen-Pu Lai, Kai Yin, Mei-Mei Zheng, Hai-Yan Tu, Wei-Bang Guo, Liang Li, Shou-Heng Lin, Zhen Wang, Lu Zeng, Ben-Yuan Jiang, Zhi-Hong Chen, Qing Zhou, Xu-Chao Zhang, Jin-Ji Yang, Wen-Zhao Zhong, Xue-Ning Yang, Bin-Chao Wang, Yi Pan, Hua-Jun Chen, Fa-Man Xiao, Hao Sun, Yue-Li Sun, Xiao-Yan Bai, E.-E. Ke, Jia-Xin Lin, Si-Yang Maggie Liu, Yangqiu Li, Oscar Junhong Luo, Yi-Long Wu
Publikováno v:
Cell Reports, Vol 43, Iss 8, Pp 114613- (2024)
Summary: Leptomeningeal metastases (LMs) remain a devastating complication of non-small cell lung cancer (NSCLC), particularly following osimertinib resistance. We conducted single-cell RNA sequencing on cerebrospinal fluid (CSF) from EGFR-mutant NSC
Externí odkaz:
https://doaj.org/article/0665f6377f1241e58a85cf57da13bbbc
Autor:
Si-Yang Liu, Song Dong, Xue-Ning Yang, Ri-Qiang Liao, Ben-Yuan Jiang, Qun Wang, Xiao-Song Ben, Gui-Bin Qiao, Jun-Tao Lin, Hong-Hong Yan, Li-Xu Yan, Qiang Nie, Hai-Yan Tu, Bin-Chao Wang, Jin-Ji Yang, Qing Zhou, Hong-Rui Li, Ke Liu, Wendy Wu, Si-Yang Maggie Liu, Wen-Zhao Zhong, Yi-Long Wu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive (N) and nivolumab–chemotherapy (N/C) combinations based on PD-L1 expression. Eligible patients exhibited resectable clinical sta
Externí odkaz:
https://doaj.org/article/fac0f07d3dc04d809e388bf7352818af
Autor:
Yu‐Min Zhong, Ji Chen, Jie Jiang, Wen‐Bin Zhou, Ling‐Ling Gao, Shui‐Lian Zhang, Wen‐Qing Yan, Yu Chen, Dong‐Kun Zhang, Dan‐Xia Lu, Zhi‐Yi Lv, Zhi Xie, Ying Huang, Wei‐Bang Guo, Bin‐Chao Wang, Jin‐Ji Yang, Xue‐Ning Yang, Yi‐Long Wu, Xu‐Chao Zhang
Publikováno v:
Clinical & Translational Immunology, Vol 13, Iss 6, Pp n/a-n/a (2024)
Abstract Objectives Primary pulmonary lymphoepithelioma‐like carcinoma (PLELC) is a subtype of lung carcinoma associated with the Epstein–Barr virus (EBV). The clinical predictive biomarkers of immune checkpoint blockade (ICB) in PLELC require fu
Externí odkaz:
https://doaj.org/article/f6dc1728bee64dd9a6c7fb2fe41988fd
Autor:
Yi‐Long Wu, Shun Lu, Qinghua Zhou, Li Zhang, Ying Cheng, Jie Wang, Buhai Wang, Chengping Hu, Lizhu Lin, Wenzhao Zhong, Yong Song, Nong Yang, Xiaorong Dong, Jian Zhao, Haihong Yang, Hui Guo, Xiaolong Yan, Hongxu Liu, Rui Ma, Jie Lin, Siyang Liu, Chun Chen, Lifeng Wang, Chengzhi Zhou, Ming Zhou, Fang Wu, Xue‐Ning Yang, Yingying Du, Yu Yao, Yang Shao, Shaodong Hong, Jiuwei Cui, Xueping Quan, Rongrong Chen, Jiayan Wu, Jiatao Zhang, Jianya Zhou, Binchao Wang, Chao Cheng, Huijuan Wang, Jingjing Liu, Lin Wu, Yan Huang, Yukun Kuang, Yongchang Zhang, Jia Hu, Jinji Yang, Weineng Feng, Wenmei Su, Yun Fan, Fan Yang, Ming Chen, Kejing Tang, Yi Pan, Peng Shen, Anwen Liu, Haibo Zhang, Wenhua Liang, Qing Zhou, Zhiyong Ma, Xiuyu Cai, Hui Liu, Longfei Chen, Shaokun Chuai, Jianzhen Shan, Yanfang Zheng, Changxuan You, Xiaoxia Zhu, Li Li, Tongmei Zhang, Haiyan Tu, Wurong Lin, Xuchao Zhang, Penghui Zhou, Zunfu Ke, Huiying Liang
Publikováno v:
Medicine Advances, Vol 1, Iss 1, Pp 3-13 (2023)
Abstract Stage III non‐small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation
Externí odkaz:
https://doaj.org/article/628a61c2e0b7401888cbceb96adb32ce
Autor:
Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Chang-Li Wang, Ming-Wei Chen, Xiao-Zheng Kang, Wan-Pu Yan, Ri-Qiang Liao, Jin-Ji Yang, Xu-Chao Zhang, Si-Yang Liu, Qing Zhou, Yi-Long Wu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-8 (2023)
Abstract EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations and R0 resected stage IIIA-N2 non-small cell lung cancer (NSCLC) (NCT01407822)
Externí odkaz:
https://doaj.org/article/1f184cb431924c6cb798d962d9892a83
Autor:
Yi‐Fan Qi, Zhen‐Bin Qiu, Chao Zhang, Rui Fu, Xiong‐Wen Yang, Xiang‐Peng Chu, Zi‐Hao Chen, Xue‐Ning Yang, Yi‐Long Wu, Wen‐Zhao Zhong
Publikováno v:
Thoracic Cancer, Vol 13, Iss 22, Pp 3174-3182 (2022)
Abstract Background Sublobectomy for early‐stage non‐small cell lung cancer (NSCLC) remains a matter of debate. This study aimed to discuss the feasibility of sublobectomy in patients with pathological‐stage IA1‐2 confirmed as pathologically
Externí odkaz:
https://doaj.org/article/6f364a4a92fd41cea892299aef7572d4
Autor:
Zi‐Hao Chen, Zhi‐Yong Chen, Jing Kang, Xiang‐Peng Chu, Rui Fu, Jia‐Tao Zhang, Yi‐Fan Qi, Jing‐Hua Chen, Jun‐Tao Lin, Ben‐Yuan Jiang, Xue‐Ning Yang, Yi‐Long Wu, Wen‐Zhao Zhong, Qiang Nie
Publikováno v:
Thoracic Cancer, Vol 13, Iss 15, Pp 2210-2222 (2022)
Abstract Objective In recent years, the lung cancer incidence has grown and the population is younger. We intend to find out the true detection rate of pulmonary nodules and the incidence of lung cancer in the population and search for the risk facto
Externí odkaz:
https://doaj.org/article/d248db86413a41359443c33d26cdd571
Autor:
Jia−Tao Zhang, Song Dong, Li−Yan Ji, Jia−Ying Zhou, Zhi− Hong Chen, Jian Su, Qing−Ge Zhu, Meng−Min Wang, E−E. Ke, Hao Sun, Xue−Tao Li, Jin−Ji Yang, Qing Zhou, Xu− Chao Zhang, Xuan Gao, Xue−Ning Yang, Xuefeng Xia, Xin Yi, Wen−Zhao Zhong, Yi−Long Wu
Publikováno v:
Thoracic Cancer, Vol 13, Iss 9, Pp 1333-1341 (2022)
Abstract Background Starting with low metastatic capability, T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers (NSCLCs) constitute a unique tumor subset, as with a large tumor size but no regional or distant metastases. We systematically inves
Externí odkaz:
https://doaj.org/article/fbd0266b6f0b4073a1deb47c9ac00d60
Autor:
Si-Yang Liu, Hua Bao, Qun Wang, Wei-Min Mao, Yedan Chen, Xiaoling Tong, Song-Tao Xu, Lin Wu, Yu-Cheng Wei, Yong-Yu Liu, Chun Chen, Ying Cheng, Rong Yin, Fan Yang, Sheng-Xiang Ren, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Hong-Hong Yan, Song Dong, Xu-Chao Zhang, Jian Su, Jin-Ji Yang, Xue-Ning Yang, Qing Zhou, Xue Wu, Yang Shao, Wen-Zhao Zhong, Yi-Long Wu
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Adjuvant gefitinib improves outcomes in non-small cell lung cancer (NSCLC) patients compared to chemotherapy, but not in all cases. Here, the authors find genomic biomarkers of response to gefitinib in NSCLC patients from the ADJUVANT trial, and prop
Externí odkaz:
https://doaj.org/article/c64a379b331b42709e78b568f7636af6